Danaher Q3 2024 Earnings Report
Key Takeaways
Danaher reported strong third quarter results with better-than-expected revenue growth, driven by positive momentum in the bioprocessing business and market share gains in molecular testing by Cepheid. Revenues increased by 3.0% year-over-year, and non-GAAP core revenue increased by 0.5%.
Net earnings reached $818 million, with EPS at $1.12 and non-GAAP adjusted EPS at $1.71.
Revenue increased 3.0% year-over-year to $5.8 billion, while non-GAAP core revenue grew by 0.5%.
Operating cash flow was $1.5 billion, and non-GAAP free cash flow amounted to $1.2 billion.
The company anticipates a low-single digit decline in non-GAAP core revenue for Q4 2024 and full year 2024.
Danaher
Danaher
Forward Guidance
The Company anticipates that non-GAAP core revenue will decline low-single digits year-over-year for the fourth quarter 2024 and continues to expect that non-GAAP core revenue will be down low-single digits year-over-year for full year 2024.